Adriamycin treatment of advanced vulvar carcinoma.
Four consecutive patients with measurable recurrent squamous cell carcinoma of the vulva were treated with Adriamycin, in small doses approximately 45 mg/square meter of body surface area every 3 weeks. Three patients achieved objective regression of nodal metastases and residual tumor with clinical subjective benefit. Tumor control was maintained for 32, 31+, and 28+ weeks.
D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000601:surgery; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D014846:Vulvar Neoplasms / Q000188:drug therapy* / Q000601:surgery
D004317:Doxorubicin